Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Theodore Randolph to Dose-Response Relationship, Drug

This is a "connection" page, showing publications Theodore Randolph has written about Dose-Response Relationship, Drug.

 
Connection Strength
 
 
 
0.215
 
  1. Hassett KJ, Meinerz NM, Semmelmann F, Cousins MC, Garcea RL, Randolph TW. Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm. 2015 Aug; 94:220-8.
    View in: PubMed
    Score: 0.087
  2. Shomali M, Tanriverdi S, Freitag AJ, Engert J, Winter G, Siedler M, Kaymakcalan Z, Carpenter JF, Randolph TW. Dose levels in particulate-containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice. J Pharm Sci. 2015 May; 104(5):1610-21.
    View in: PubMed
    Score: 0.086
  3. St John RJ, Carpenter JF, Balny C, Randolph TW. High pressure refolding of recombinant human growth hormone from insoluble aggregates. Structural transformations, kinetic barriers, and energetics. J Biol Chem. 2001 Dec 14; 276(50):46856-63.
    View in: PubMed
    Score: 0.034
  4. Kim YS, Randolph TW, Manning MC, Stevens FJ, Carpenter JF. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem. 2003 Mar 21; 278(12):10842-50.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)